Physician profile
John Patrick Mclaughlin
NPI 1609854157
$8,944.90
in general payments reported to CMS, 2019-2025
39 companies · $2,135 in 2025
The $2,135 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $409 · 2021: $922 · 2022: $1,042 · 2023: $1,629 · 2024: $1,869 · 2025: $2,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,632.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,800.39 | 2019-2025 | |
| Janssen Biotech, INC. | $1,070.05 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $649.04 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $622.02 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Madrigal Pharmaceuticals | $505.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $352.31 | 2021-2023 | Zeposia |
| Pfizer INC. | $349.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $245.39 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $238.60 | 2019-2025 | Sucraid |
| Ardelyx, INC. | $224.45 | 2023-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $206.74 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $135.56 | 2021-2024 | Dificid |
| Celltrion USA INC. | $133.29 | 2024-2025 | Vegzelma |
| Gilead Sciences, INC. | $120.56 | 2019 | |
| Boston Scientific Corporation | $117.84 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.